Health Disparities in Cancer Patients Receiving Molecular Testing for Biomarker – Directed Therapy
Estela Rodriguez shared on X:
“Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
- Retrospective analysis of 12K patients with Caris Life Sciences molecular testing (large cohort of Black patiens-25 percent)
- NO differential diagnosis in OS for patients who receive molecular testing
- Differential diagnosis in TP53, APC, KRAS, and PIK3CA mutation frequency in select tumor types (? impact ancestry) Elisabeth Heath et al.
Authors: Elisabeth Heath, Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani, Mohammed N. Al-Hallak, Anthony F. Shields, Jailan A. Elayoubi, Ira S. Winer, Frank C. Cackowski, Gary A. Puckrein, Gilberto de Lima Lopes, Nathaniel Jones, Ralph J. Hauke, Samuel A. Kareff, Milan Radovich, George W. Sledge, David B. Spetzler, Gregory A. Vidal, John L. Marshall.“
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023